FARMINGDALE, N.Y., Oct. 24, 2023 /PRNewswire/ -- Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced that the US Department of Defense (DoD), through the US Army Medical Research and Development Command and the US Army Medical Research Acquisition Activity, has awarded the Company $5.88 million to advance the development of its CodaVax-DENV, a tetravalent live attenuated dengue vaccine program. This complements a $4.4 million DoD award granted in 2022 as part of the Joint Warfighter Medical Research Program.
FARMINGDALE, N.Y., Oct. 11, 2023 /PRNewswire/ -- Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced the late-breaking presentation of positive clinical data for its CoviLiv™ COVID-19 vaccine candidate at the upcoming IDWeek 2023 annual meeting, taking place in Boston on October 11-15, 2023.
Codagenix is moving its rational virus design platform forward with a new Phase I trial of its live attenuated respiratory syncytial virus (RSV) vaccine in children.
FARMINGDALE, N.Y., May 10, 2023 /PRNewswire/ -- Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced that it has initiated dosing in a pediatric Phase 1 study evaluating CodaVax™-RSV, a live-attenuated, intranasal vaccine candidate for the prevention of disease caused by respiratory syncytial virus (RSV). The study has an age de-escalation, dose escalation design specifically evaluating safety and immunogenicity in the 6-month to 5 year-old population. The trial is being conducted under US IND and the FDA has also granted Fast Track designation.
FARMINGDALE, N.Y., March 28, 2023 /PRNewswire/ -- Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for live-attenuated viral vaccines and immuno-oncology therapeutics, today announced that Kimber Poffenberger, Ph.D., has been appointed Chief Strategy Officer.
FARMINGDALE, N.Y. and CAMBRIDGE, Mass., Feb. 15, 2023 /PRNewswire/ -- Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for live-attenuated viral vaccines and immuno-oncology therapeutics, today announced the completion of a $25 million Series B extension financing, with participation from a new investor, the Serum Institute of India Pvt. Ltd., along with existing investors Euclidean Capital and Adjuvant Capital.
While ImmunityBio is involved in arbitration with Sorrento Therapeutics, which filed for bankruptcy this week to protect from the potential capital burden, the California biotech is pulling together $50 million.
FARMINGDALE, N.Y., Nov. 2, 2022 /PRNewswire/ -- Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CodaVax™-RSV, an intranasal, live-attenuated vaccine candidate, for the prevention of respiratory syncytial virus (RSV).
Codagenix and the Serum Institute of India (SII) have commenced subject dosing in a Phase III clinical trial of the intranasal Covid-19 vaccine CoviLiv.
FARMINGDALE, N.Y., Oct. 26, 2022 /PRNewswire/ -- Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, in collaboration with the Serum Institute of India Pvt. Ltd., today announced dosing has been initiated in an international, multi-center, randomized placebo-controlled Phase 3 clinical trial of CoviLiv. This Phase 3 efficacy evaluation is part of the World Health Organization's (WHO) Solidarity Trial Vaccines to support the development of second-generation COVID-19 vaccines with greater efficacy, greater protection against variants of concern, longer duration of protection, improved storage and/or simplified delivery with needle-free administration.